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Hereditary nonpolyposis colorectal cancer (HNPCC) is frequently associated with constitutional mutations in a class of genes
involved in DNA mismatch repair. We identified 32 kindreds, with germline mutations in one of three genes hMSH2, hMLH1 or
hMSH6. In this study, we purposed to evaluate how many high-risk individuals in each family underwent genetic testing: moreover, we
assessed how many mutation-positive unaffected individuals accepted colonoscopic surveillance and the main findings of the
recommended follow-up. Families were identified through a population-based registry, or referred from other centres. Members of
the families were invited for an education session with two members of the staff. When a kindred was consistent with HNPCC,
neoplastic tissues were examined for microsatellite instability (MSI) and immunohistochemical expression of MSH2, MLH1 and MSH6
proteins. Moreover, constitutional mutations were searched by SSCP or direct sequencing of the whole genomic region. Of the 164
subjects assessed by genetic testing, 89 were gene carriers (66 affected – that is, with HNPCC-related cancer diagnosis – and 23
unaffected) and 75 tested negative. Among the 23 unaffected gene carriers, 18 (78.3%) underwent colonoscopy and four declined.
On a total of 292 first degree at risk of cancer, 194 (66.4%) did not undergo genetic testing. The main reasons for this were: (a)
difficulty to reach family members at risk, (b) lack of collaboration, (c) lack of interest in preventive medicine or ‘fatalistic’ attitude
towards cancer occurrence. The number of colorectal lesions detected at endoscopy in gene carriers was significantly (Po0.01)
higher than in controls (noncarriers). We conclude that a large fraction of high-risk individuals in mutation-positive HNPCC families
does not undergo genetic testing, despite the benefits of molecular screening and endoscopic surveillance. This clearly indicates that
there are still barriers to genetic testing in HNPCC, and that we are unable to provide adequate protection against cancer
development in these families.
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Lynch syndrome or hereditary nonpolyposis colorectal cancer
(HNPCC) is an inherited disease that accounts for 1–3% of all
colorectal malignancies (Lynch and Smyrk, 1996; Peel et al, 2000).
On a clinical ground, HNPCC is characterised by increased
susceptibility to colorectal and several other neoplasms (especially
endometrium, ovary, small bowel and urothelium), early age of
cancer onset (frequently under 50 years), a proclivity towards
tumours in the right colon (from the cecum to the splenic flexure)
and frequent multiple primary tumours in the same patient (Lynch
and Smyrk, 1996). Molecular investigations have shown that most
HNPCC families are associated with constitutional mutations in a
class of genes (called hMSH2, hMLH1, hMSH6, hPMS2 and
probably others) which are components of a DNA mismatch repair
pathway (Wheeler et al, 2000; Calvert and Frucht, 2002). As a
consequence of their inactivation, cells show a generalised
genomic instability, which is particularly evident at microsatellite
loci (microsatellite instability, MSI) (Aaltonen et al, 1993; Ionov
et al, 1993; Thibodeau et al, 1993).
Since mutations in any of the DNA mismatch repair genes
confer a lifetime risk of cancer of 80–85% (Lynch and Smyrk,
1998a,b), regular endoscopic controls in individuals at risk (gene
carriers) and removal of all premalignant lesions reduce the
colorectal cancer rate in HNPCC families (Jarvinen et al, 1995).
There are objective reasons, therefore, for recommending a close
endoscopic surveillance to first-degree relatives of the affected
individuals, especially in those subjects in whom this increased
susceptibility has been further confirmed by genetic testing.
Despite the potential benefit, genetic testing and the possible
identification of gene carriers may represent a source of stress and
anxiety in a given family. This is due to the psychological
condition of being genetically ‘different’ from the rest of the
population, to loss of privacy and possible discrimination in many
social activities (Garber et al, 1997). Indeed, in a recent
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sinvestigation, Lerman et al (1999) showed that, in four large
HNPCC kindreds, more than 50% of the high-risk family members
refused further contacts with the investigators or declined genetic
counselling. The low rate of acceptance of genetic testing – which
was rather unexpected – should raise some concerns on the
expected widespread diffusion of this new form of preventive
medicine.
Since the availability of genetic testing for hMSH2, hMLH1 and
hMSH6 gene mutations, we could identify 32 HNPCC families with
germline alterations in one of these genes. In the present
investigation, we analysed our study group with three specific
objectives: first, to evaluate how many high-risk individuals in
each family underwent genetic testing for the search of constitu-
tional mutations; second, to ascertain whether mutation-positive
unaffected individuals made a proper use of the test (ie, accepted
endoscopic surveillance) and, third, to investigate the main
findings of endoscopic surveillance in gene carriers.
MATERIAL AND METHODS
Selection of families
Hereditary nonpolyposis colorectal cancer families were assessed
in three different centers: the University of Modena (Northern
Italy, Region Emilia-Romagna), the Catholic University Medical
School in Rome (Central Italy, Region Lazio) and the Aviano
Cancer Center (Northern Italy, Region Friuli-Venezia Giulia). In
Modena, the families were identified through a multistep approach
based on a colorectal cancer registry instituted in 1984 (Ponz de
Leon et al, 1987; Ponz de Leon et al, 1999). All tumours of the large
bowel diagnosed in the population (265227 residents at the 1991
census) were registered. The neoplasms were classified according
to the International classification of Diseases for Oncology, 9th
revision (ICD-O, 1983). Definitions such as ‘carcinoma in situ’,
‘neoplastic foci’ or ‘severe dysplasia’ were not considered as cancer
unless there was a clear infiltration of the neoplastic tissue through
the muscularis mucosae. Nuclear pedigrees could be obtained in
94% of the registered patients (2462 in the 15-year period 1984–
1998). The pedigrees were classified and subdivided according to
the presence of clinical criteria indicative of an increased
susceptibility to hereditary colorectal cancer (Lynch and Smyrk,
1996). Families showing two or more of these clinical criteria
(ie, early age of cancer onset, aggregation of tumours in a sibship,
‘verticality’, proximal location in the large bowel, multiple
primaries) were contacted and the pedigrees extended to second-
and third-degree relatives. As far as possible, the diagnosis of
cancer among family members was verified by histological records,
clinical charts or death certificates. In the two other Centres
involved in the study (Rome and Aviano), the procedure leading to
the identification of HNPCC families was similar to that followed
in Modena (ie, definition of nuclear pedigrees, extension of
suspected family trees and verification of cancer); the areas,
however, were not covered by cancer registries, and individual
patients or families with suspicion of HNPCC were referred to the
investigators from surgical or endoscopic units operating in those
districts. Of the 32 families with constitutional mutations, 25 met
the Amsterdam criteria II (Vasen et al, 1999) and seven maintained
a strong clinical suspicion of HNPCC, because of familial
aggregation and early-onset colorectal cancer.
When a kindred showed clinical suspicion of HNPCC, the family
doctor was usually contacted for obtaining further information.
Subsequently, the proband or other family members were invited
by telephone for an education session in one of the centres
involved in the study. Families were approached by Internists in
Modena, Medical Geneticists in Rome and Gastroenterologists in
Aviano. During the session, two members of the staff gathered all
relevant information concerning family members (especially
cancer development), traced an accurate and extended genealogi-
cal tree and required clinical charts or other certifications in order
to verify the cancer status. The investigators discussed the general
principle of cancer inheritance, advantages and limitations of
genetic testing, options of endoscopic surveillance and the possible
impact of environmental factors (diet, lifestyle) on cancer-risk
reduction. Booklets containing all this information, and further
suggestions on diet and style of life, were given to family members
at risk. When a kindred was consistent for HNPCC, the successive
step was the analysis of microsatellite instability in tumour
samples. In the presence of a family history suggestive of Lynch
syndrome and of a MSIþ tumour, genetic testing was offered to
affected probands from high-risk families, without any charge for
the patient and after informed consent. Once a mutation was
detected, the family was recontacted and genetic testing was
offered to other family members at risk. In most cases, this
occurred within 1 year from cancer diagnosis in the proband.
Moreover, family doctors, other physicians and collaborative
relatives were involved in the attempt to collect further relevant
information, particularly with regard to the most distant branches
of the family or to individuals living in other regions. Mutation
carriers were informed about the need of early colonoscopic
surveillance (starting at age 20–25 years), possible benefits and
limits of additional screening procedures (endometrial ultrasounds
and aspiration biopsy; upper digestive tract endoscopy) and other
options aimed at reducing cancer risk (prophylactic interventions,
changes in diet and life-style). Noncarriers were reassured, though
we made it clear that colorectal cancer is an extremely common
disease and that there is large consensus to screen the general
population – through fecal occult blood test and lower endoscopy
– around the age of 50 years.
Microsatellite instability
At least one colorectal lesion in each of the 32 families was assessed
for MSI, and this was detected in all cases. DNA was extracted from
neoplastic and paired normal mucosa, and instability was
evaluated with five markers (mono and dinucleotides), as already
described (Pedroni et al, 1999). Neoplasms showing instability in
two or more loci were scored as unstable (MSIþ). PCR products
from colorectal tumours and the corresponding normal mucosa of
the same patient were loaded in adjacent lanes on a standard 6%
denaturating polyacrylamide gel, and visualised by auto-
radiography.
MSH2, MLH1 and MSH6 protein expression
Details of the procedure have already been given (Pedroni et al,
1999). Briefly, formalin-fixed and paraffin-embedded tumour
samples from the affected subjects in each family were sectioned
at 6mm, deparaffined and rehydrated. After antigen retrieval,
monoclonal antibodies to full-length hMSH2, hMLH1 and hMSH6
proteins (G168-15, G129-1129, Pharmingen and Clone 44 Trans-
duction Labs, USA) were used at 1:40 to 1:2000 dilution. Tissue
samples were stained using diaminobenzidine as chromogen,
according to the Nexes Automatic Staining System (Ventana,
Strasburg, France). Lesions were considered positive for protein
inactivation when a complete absence of nuclear staining was
evident in tumour cells against evident nuclear staining of adjacent
normal epithelial and stromal cells.
Mismatch repair genes mutation analysis
As previously reported (Viel et al, 1997), constitutional mutations
in the three main DNA mismatch repair genes (hMSH2, hMLH1
and hMSH6) were studied either by single-strand conformation
polymorphism (SSCP) or by direct sequencing of the whole
genomic region and flanking intron borders using the Big Dye
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sSequencing Kit (Applera, Foster City, CA, USA) and an applied
Biosystem Authomated Sequencer (Applera) on DNA isolated
from blood white cells. All families which tested negative by SSCP
were subsequently analysed by direct sequencing.
Statistical analysis
Differences in the occurrence of polyps at endoscopy between gene
carriers and noncarriers were evaluated with Z tests for
independent proportions, when considering the number of
patients with or without polyps. When taking into account the
number of lesions, their frequency was applied to the appropriate
persons/years at risk in the two groups (mutation þ and mutation
 ), and summary w
2 tests were used – with the Statistical Package
for Social Sciences (SPSS) software – to calculate its statistical
significance.
RESULTS
Figure 1 shows the strategy that has been followed for the
identification of kindreds with inherited colorectal tumours
attributable to germline mutations of the main DNA mismatch
repair genes. In registered or referred patients, accurate genealo-
gical trees were traced, and, on this basis, a high-risk group for
genetic cancer was defined, including HNPCC (according to the
Amsterdam Criteria), suspected HNPCC (Park et al, 2002) and
early-onset (before the age of 50 years) colorectal cancer,
representing some 10–15% of all investigated patients with
malignancies of the large bowel. As a successive step, microsatellite
instability was assessed in this high-risk group; in MSIþ cases, the
expression of the protein encoded by the three main mismatch
repair genes was evaluated by immunohistochemistry in tumour
samples. Lack of protein expression was followed by search of
constitutional mutations of the corresponding gene, in the
proband and in other family members. With this algorithm, 32
families with germline mutations were identified, between 1994
and 2001.
Details of individual families characterised by constitutional
mutations (Viel et al, 1997, 1998; Lucci-Cordisco et al, 2001) are
shown in Table 1. A total of 164 individuals could be assessed by
genetic testing (on average, five per family); 89 were gene carriers
(66 affected and 23 nonaffected) and 75 tested negative (ratio: 1.18,
not far from the 1:1 expected for autosomal dominant transmis-
sion). Among the 23 unaffected gene carriers, 19 (82.6%) under-
went pancolonoscopy within 1–2 years from the test results, while
four declined. Reasons for denial were young age (19 and 21 years,
two subjects), ‘lack of time’ associated with some fear of invasive
procedures in the other two. On a total of 292 first-degree relatives
of affected individuals over the age of 20 years, 194 (66.4%) did not
undergo genetic testing. The number of subjects who could be
assessed varied from family to family, but was apparently
unrelated to the dimension of the kindred, site of origin and level
of education. The main reasons for not executing genetic tests
were: (a) difficulty (or impossibility) to reach and contact family
members (65%); (b) lack of collaboration (15%); (c) lack of
interest in preventive (or ‘predictive’) medicine or ‘fatalistic’
attitude towards cancer occurrence or unspecified reasons (20%).
Most mutations were found in hMSH2 (16; 50%) or hMLH1 (14;
44%) genes; families MO-1, MO-2, MO-26 and MO-27 showed the
same germline alteration. The four families segregating this
unusual mutation were resident in the same area, a finding which
could be explained by a founder effect (manuscript submitted for
publication).
Table 2 shows the main endoscopic findings of gene carriers
who accepted to be screened. As a control group, we selected those
noncarriers who underwent colonoscopy before knowing the test
results or despite their low risk status, owing to anxiety or need of
more reassuring procedures. Although gene carriers were younger
than controls (average difference: 5 years), the number of lesions
(adenomatous or hyperplastic polyps, or carcinomas) detected at
endoscopy was significantly (Po0.001) higher in the carriers.
Moreover, colorectal lesions were found in seven high-risk subjects
(of 19, 36.8%), but in two controls only (of 19, 10.5%) (Po0.01).
The length of follow-up was similar in the two groups (4.972.6 vs
6.572.4 years in controls), while the number of colonoscopic
investigations/patient was 1.50 in the high-risk group and 1.45 in
noncarriers.
DISCUSSION
The results of the present investigation show that a large fraction
of high-risk individuals in mutation-positive HNPCC families does
not undergo genetic tests, despite their availability. Among
examined subjects, the large majority of gene carriers follows the
recommendations, and is willing to undergo colonoscopic
surveillance. Despite the relatively young age of gene carriers,
the results of endoscopy show an increased risk for polyps and
adenomas.
Our findings are similar to those obtained by Lerman and
collaborators with American HNPCC families, in whom 43% only
of high-risk subjects participated in their counselling and testing
program (Lerman et al, 1999). Among the reasons for this relative
lack of success, the authors gave emphasis to low education and
frequent presence of depression symptoms in their study group. It
should be noted that the American experience is based on the
analysis of four large kindreds, and that most individuals at risk
could be contacted directly, by letter or telephone. In our study, 32
families scattered in various Italian regions were analysed, and this
prevented us from evaluating the role of strictly personal factors,
such as the level of education and presence of depression.
Once the accurate examination of a family tree raises the
suspicion of HNPCC, molecular analysis can be undertaken to
definitely establish the diagnosis. As recently pointed out by
Terdiman (2001), this is not a truly essential step, since the
fundamental factor for saving lives is to identify high-risk
individuals based on clinical grounds, and to ensure that they
receive appropriate surveillance, whether detected to have a
Registered or referred patients
Examination of family tree
HNPCC
Suspected HNPCC
Early onset
Microsatellite
instability (MSI)
(50 − 15%)
MSI (+)
Immunohistochemistry
(MSH2, MLH1, MSH6)
MSI (−)
Selective search of
constitutional mutations
Clinical follow-up
NO further
Sporadic cancer (85 − 90%)
Familiality (aspecific)
Figure 1 Clinical and molecular strategies developed for the selection
and identification of HNPCC. As far as the experience in Modena is
concerned (where a specialised colorectal cancer Registry was instituted in
1984), the number corresponding to each category, for the period 1984–
1998, are the following. Registered patients: 2462. Sporadicþfamilial cases:
2207. HNPCCþsuspected HNPCCþearly-onset cases: 255. MSIþ: 53.
Lack of protein expression: 21 (immunohistochemistry). Families which
underwent genetic testing: 15. Families with constitutional mutations: 12.
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smutation or untested. Indeed, the fraction of HNPCC in which
mismatch repair gene mutations can be identified ranges between
30 and 60% of all families (the fraction is even lower in the so-
called suspected HNPCC), and this means that in approximately
half of these kindreds endoscopic surveillance should be initiated
simply on a clinical basis (Aaltonen et al, 1998; Lynch and Smyrk,
1998a,b; Wijnen et al, 1998).
However, when a constitutional mutation is found in a HNPCC
family, we feel ‘a step forward’, in the sense that high-risk
individuals can be precisely identified, and endoscopic surveil-
lance can be limited to gene carriers, thus avoiding unnecessary
early investigations in many subjects. It is rather disappointing,
therefore, that both the study of Lerman et al (1999) and the
present investigation clearly show that there are still barriers to the
widespread diffusion of genetic testing. In our experience, the
main limiting factor was the difficulty in reaching and contacting
directly all family members at risk. As indicated by current
guidelines, we preferred to adopt a ‘soft’ attitude, avoiding direct
telephone calls to distant relatives of the proband and encouraging
relatives to talk each other about the risk of cancer running in the
family, and the possibilities of prevention and early diagnosis.
Moreover, whenever possible, family doctors were contacted and
informed about the family history. However, their involvement –
though occasionally helpful – had a limited impact in alerting
high-risk individuals. It is of interest that the relatively more active
attitude of Lerman et al (1999) and our less interfering approach
gave basically the same results. Lack of collaboration and poor
interest in the novel approaches offered by molecular medicine
Table 2 Endoscopic surveillance and tumour occurrence in gene carriers and in controls (mutation negative)
Groups n
Mean age at
first endoscopy (years)+s.d.
All polyps
detected Adenomas
No. patients
with polyps
Other neoplasms
developed during follow-up
Mutation+
a 19 33.178.7 17* 11** 7 (36.8%)*** 3 (endometrium, thyroid, colon)
Mutation  
b 19 38.5713 3 3 2 (10.5%) 2 (endometrium, breast)
aGene carriers, that is, first-degree relatives of affected individuals in whom genetic testing showed the presence of a constitutional mutation.
bMutation negative, that is, first-
degree relatives of affected individuals in whom genetic testing showed wild-type gene. *Po0.001 by summary w
2 test. **P¼0.003 by summary w
2 test. ***Z¼3.22, Po0.01.
Table 1 Individual families characterised by germline mutations in DNA mismatch repair genes during the period 1994–2001
Family Gene Mutation
Investigated
individuals
Mutation positive
affected
a/nonaffected
b
Mutation
negative
c
Total individuals at
risk
d
Individuals at risk
nonevaluated
e (%)
f
1. MO-1 hMLH1 2270ins 10 4/2 4 8 2
2. MO-2 hMSH2 1243–1246del 4 1/1 2 11 8
3. MO-4 hMLH1 IVS17(+5)G4C 4 2/0 2 14 12
4. MO-10 hMSH2 IVS6(+3)A4T 14 5/0 9 32 23
5. MO-20 hMLH1 2270ins 2 2/0 0 12 12
6. MO-27 hMLH1 2270ins 7 4/0 3 12 9
7. MO-29 hMLH1 2270ins 11 2/3 6 21 12
8. MO-32 hMSH2 W345X 1 1/0 0 4 4
9. MO-39 hMSH2 2647del 17 5/1 11 31 19
10. MO-35 hMSH2 IVS5(+3)A4T 6 3/2 1 8 5
11. MO-41 hMSH6 2984del 4 1/1 2 5 2
12. MO-44 hMLH1 1542ins 2 2/0 0 5 5
13. RM-1 hMLH1 Del 2.5kb 4 3/0 1 5 4
14. RM-2 hMLH1 597–598del 7 2/2 3 11 6
15. RM-3 hMSH2 1497del 3 2/1 0 8 7
16. RM-4 hMSH2 1705insGA 4 1/0 3 3 0
17. RM-5 hMLH1 1520insT 13 4/2 7 15 6
18. RM-6 hMLH1 1846–1848del 4 2/0 2 7 5
19. AV-24 hMLH1 IVS7(-2)A4G 5 2/1 2 11 8
20. AV-2 hMLH1 Q301X 10 2/1 7 8 1
21. AV-14 hMLH1 1783–1784del 3 1/0 2 2 0
22. AV-20 hMLH1 Del 2.5kb 1 1/0 0 2 2
23. AV-4 hMSH6 1960insGTGA 1 1/0 0 0 0
24. AV-17 hMSH2 Q824X 6 2/1 3 6 2
25. AV-39 hMSH2 S473X 4 1/1 2 4 1
26. AV-28 hMSH2 C778X 2 1/0 1 5 4
27. AV-52 hMSH2 399del 7 4/2 1 8 5
28. AV-56 hMSH2 840insT 1 1/0 0 8 8
29. AV-60 hMSH2 IVS6(-2) A4C 1 1/0 0 2 2
30. AV-68 hMSH2 R406X 2 1/1 0 15 14
31. AV-91 hMSH2 Q824X 3 1/1 1 4 2
32. AV-87 hMSH2 C697R 1 1/0 0 5 4
Total hMLH1 (14) 164 66/23 75 292 194 (66.4%)
hMSH2 (16)
hMSH6 (2)
aPatients affected by colorectal (or other malignancy of the HNPCC system) at diagnosis.
bFirst-degree relatives in whom genetic testing showed constitutional mutations.
cFirst-
degree relatives in whom genetic testing showed wild-type gene.
dIn each family, first-degree relatives of affected individuals over the age of 20 years.
eIn each family, individuals at
risk who did not undergo genetic testing.
fPercent of total individuals at risk.
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swere relevant factors limiting the diffusion of genetic testing also
within our HNPCC families. We noticed that a fatalistic attitude to
cancer occurrence is still frequent and, surprisingly, often
independent by the level of education. To the arguments that
cancer was so common among close relatives and that there are tests
available for knowing the level of risk, answers such as ‘I do not
want to know my risk level, I prefer not to be upset’ or ‘Cancer is so
frequent, and there is no way to escape it’, were not uncommon.
The fact that the large majority of mutation carriers underwent
endoscopic surveillance is more reassuring. We are not surprised
that some individuals hesitated before accepting endoscopy in
their 20s or 30s, simply on the basis of a test result. Colonoscopy,
even with proper sedation, remains an embarrassing and often
painful procedure, which requires a long and disturbing prepara-
tion. However, our data suggest that surveillance is acceptable to
most, if not all, mutation carriers. Noncarriers can be reassured
about their low risk of colorectal cancer and the fact that early
colonoscopy is not necessary. Nevertheless, some 30% of them
underwent endoscopic controls before the age of 40 years, usually
because of anxiety. Since the lifetime risk of colorectal cancer in
the Western population is in the order of 5–6% (Black et al, 1997),
and the same holds true for noncarriers within HNPCC families,
we believe that the attention of mutation-negative individuals to
the possible event of common malignancies should not be
completely discouraged. Indeed, endoscopy in noncarriers showed
adenomatous polyps in two of them (10.5%), at an average age of
38 years (Table 2). Finally, the finding of early-onset polyps in one
out of three of gene carriers and the frequency of adenomatous
lesions are not surprising, and confirm previous investigations
(Jarvinen et al, 2000; de Vos tot Nederveen Cappel et al, 2002).
These results further emphasise the importance of a strict
endoscopic surveillance in all individuals at risk, in HNPCC
families, starting at age 20–25 years (Lindblom and Nordenskjold,
1999, Giardiello et al, 2001). Moreover, they reinforce the concept
that cancer in these families develops through the adenoma–
carcinoma sequence, as in sporadic colorectal cancer.
In conclusion, the main message of the present investigation is
that, at present, there are still relevant barriers to genetic testing in
HNPCC families and, consequently, we are not able to provide
adequate protection against cancer development even in kindreds
with identified constitutional mutations. Better education of
patients, institution of specialised units entirely devoted to
inherited tumours and further collaboration with mass media
might help molecular medicine to reach the objective of saving
lives (Julian-Reynier et al, 1996; Lee et al, 2002).
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